CR3-RP has been identified as a promising marker for Candida infections, with synthetic CR3-RP eliciting significant IgM and IgA antibody responses in patients with recurrent vulvovaginal candidiasis [156]. This evidence concerns the gene CRIPTO3 and vulvovaginal candidiasis.